PDLIM7 and cancer: This study highlights the critical role of LMP1/2A in suppressing hematological and solid tumors by enhancing CD8+ T cell-mediated immune surveillance, providing a basis for the development of novel therapeutic and preventive strategies targeting MHC class I-negative malignancies across a broad range of cancer types.